Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma

Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma

Abstract C–C motif chemokine ligand 2 (CCL2) is a monocyte chemoattractant that promotes metastatic disease and portends a poor prognosis in many cancers. To determine the potential of anti-CCL2 inhibition as a therapy for recurrent metastatic disease in neuroblastoma, a mouse model of minimal resid...

Full description

Bibliographic Details
Main Authors: Danny Lascano, Michael J. Zobel, William G. Lee, Stephanie Y. Chen, Abigail Zamora, Grace E. Asuelime, So Yung Choi, Antonios Chronopoulos, Shahab Asgharzadeh, Araz Marachelian, Jinseok Park, Michael A. Sheard, Eugene S. Kim
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-46968-2

Internet

https://doi.org/10.1038/s41598-023-46968-2

Similar Items